#CDMO #BioCina #NovaCina #Perth, Western Australia

BioCina and NovaCina Join Forces: A New Era for CDMO

In a landmark announcement, two leading Global Contract Development and Manufacturing Organizations (CDMO), BioCina and NovaCina, have merged to form a formidable entity poised to revolutionize the industry. The newly consolidated organization will continue to operate under the venerable name of BioCina and signify a new chapter in contract manufacturing for small molecules and biopharmaceuticals.

This merger reflects a strategic move to better serve the growing demand for high-quality integrated manufacturing solutions across various markets, including the USA, Europe, Asia, and Australia. With a fully integrated entity, BioCina is set to offer a comprehensive range of services that encompasses everything from cell line development and process development to the commercial and clinical manufacturing of drugs and sterile fill-finish for pharmaceutical products.

The synergy of this merger combines BioCina's renowned expertise in process development with NovaCina's state-of-the-art filling and finishing facility based in Perth, Western Australia. This plant has an impressive track record, having manufactured over 600 biologicals and small molecules. Both organizations boast skilled technical teams with an average of over ten years of experience, ensuring that clients can expect optimized, customer-focused solutions managed under one roof.

BioCina’s commitment to excellence is underscored by its robust regulatory history, including successful approvals from several eminent regulatory bodies such as the FDA, EMA, TGA, and Health Canada. Furthermore, developers will benefit from Australia’s notable tax incentives, which can reach up to 48.5% for CDMO programs, making it an attractive destination for pharmaceutical companies.

Mark W. Womack, the current CEO who has witnessed the rapid growth and development of BioCina in recent years, will lead the newly merged company. Recognized for his visionary leadership, Womack’s tenure at BioCina has been marked by a strong emphasis on operational reliability and a customer-centric culture.

The merger aims to address the industry's escalating complexity and the need for reliable CDMO partnerships. New drug developers and seasoned biopharmaceutical companies alike are in search of trustworthy CDMO entities that can streamline their path to market with efficiency and flexibility in regulatory approvals. Masood Tayebi, co-founder and CEO of Bridgewest Group, which oversees both BioCina and NovaCina, expressed confidence that this union would enhance industry standards and capabilities, providing an unparalleled package of services to their clients.

“It perfectly aligns the strengths of both companies,” Tayebi noted. “We expect great things as a single unit, especially with Mark at the helm.”

BioCina’s expansive facilities in Adelaide, South Australia, and Perth are equipped to handle a wide range of pharmaceutical products, solidifying the organization’s position as a leading CDMO. With a commitment to maintaining the highest international quality standards, BioCina ensures compliance through rigorous regulatory inspections that affirm its standing in the global marketplace. The consolidated entity promises to set new benchmarks for quality, reliability, and efficiency in manufacturing.

As one of Australia’s fastest-growing biopharmaceutical firms, BioCina earned the prestigious accolade of